Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CDT Equity Inc. (NASDAQ: CDT) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on CDT’s corporate actions, financial reporting, governance decisions, and strategic developments as it operates as a data-driven biopharmaceutical development company.
CDT’s current reports on Form 8-K include items such as the approval and implementation of reverse stock splits, amendments to its certificate of incorporation, and the formal change of its corporate name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Filings also describe stockholder approvals related to the company’s stock incentive plan, the authorization of additional shares for equity awards, and matters voted on at annual and special meetings.
Other 8-K filings address topics like non-reliance on previously issued interim financial statements and planned restatements. For example, CDT has reported on the reclassification of certain milestone payments to Sarborg Limited from research and development expense to an acquired diagnostic asset, explaining how this affects its condensed consolidated financial statements. These disclosures help readers understand how the company applies accounting standards to its AI and diagnostic-related agreements.
Proxy materials, such as definitive proxy statements on Schedule 14A, provide further insight into CDT’s governance structure, director elections, auditor ratification, and proposals to amend stock plans. They also outline voting requirements, quorum definitions, and procedural details for virtual annual meetings.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, making it easier to interpret complex sections of 10-Ks, 10-Qs, 8-Ks, and proxy statements. Real-time updates from EDGAR ensure that new CDT filings, including any Form 4 insider transaction reports or future registration statements, are quickly reflected. This allows investors and researchers to review CDT’s regulatory history, corporate actions, and reporting practices in a structured, accessible format.
CDT Equity Inc. registers 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction. The Company states it will not receive any proceeds from sales by the selling stockholders and the shares may be sold from time to time at market, negotiated or private prices. The prospectus notes a 1-for-25 reverse stock split effective March 26, 2026 and references an ELOC capacity of $25.0 million.
CDT Equity Inc. director Olsen Ulrik K filed an initial Form 3 reporting his holdings of the company’s Common Stock. The filing shows direct ownership of 233,585 shares, establishing his baseline equity position as an insider. The filing does not reflect any new buy or sell transactions.
CDT Equity Inc. announced changes to its board leadership and membership. The company appointed Ulrik Olsen, age 50, as a director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees. The board determined he meets independence requirements under Nasdaq and the Securities Exchange Act.
Olsen is based in New Zealand, where Sarborg Limited, in which CDT holds a 20% equity stake, has its principal place of business. He brings experience in commercial property, including director roles at Scarborough Group Limited since 2017 and managing director of OB Energy since 2018. He will participate in CDT’s non-employee director compensation program.
Freda Lewis-Hall resigned from the board and her committee roles for family health reasons, with no disagreement related to company operations. Chele Chiavacci Farley was appointed chairperson of the board and of the Nominating and Corporate Governance Committee, and Simon Fry was appointed chairperson of the Audit Committee.
CDT Equity Inc. is registering 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers (i) up to 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and (ii) 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction (including shares issued upon cashless exercise of pre-funded warrants). The Company will not receive proceeds from resales and has an at‑the‑market style ELOC with capacity up to $25.0 million under which sales are at the Company’s discretion.
CDT Equity Inc. reports its annual overview as an early-stage, data-driven pharmaceutical developer that licenses clinical compounds from AstraZeneca and seeks to out-license them after pre-clinical and early clinical work. The company focuses on solid-form chemistry and artificial intelligence partnerships to reposition assets for autoimmune disease, idiopathic male infertility, oncology, dermatology, rare disease and animal health.
The report highlights a going concern warning, noting substantial doubt about CDT Equity’s ability to continue operating without additional funding and acknowledging potential dilution from future equity issuance. CDT Equity details multiple related-party agreements, including extensive AI and analytics work with Sarborg Limited and animal-health development with Manoira, as well as consulting and CRO arrangements to advance its pipeline while maintaining a lean, asset-light model.
CDT amends its prospectus supplement to increase the amount of common stock that may be sold under its Sales Agreement with A.G.P./Alliance Global Partners to $76,077,218 as of April 2, 2026. This Amendment upgrades the previously stated offering capacity of $3,556,586 to the larger aggregate amount because the company’s public float exceeded $75.0 million as of March 24, 2026, allowing use of General Instruction I.B.1 of Form S-3. The prospectus notes the company is an emerging growth company and a smaller reporting company, and discloses a last reported sale price of $5.10 per share on April 1, 2026.
CDT Equity Inc. filed a Form 12b-25 notifying the SEC that it could not timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company expects to file the Form 10-K on or before the fifteenth calendar day following the prescribed due date. CDT Equity anticipates a net loss of approximately $39.1 million for 2025, an increase of about $21.3 million versus 2024; these amounts remain under review by its independent registered public accounting firm.
CDT Equity Inc. reported indirect restructuring transactions involving entities associated with Mark Taylor. On February 19, 2026, Prospect Finance Limited transferred 46,902 shares of Common Stock and pre-funded warrants to purchase 9,968,931 shares of Common Stock to a third party for no consideration.
Following stockholder approval at a special meeting, on March 17, 2026 Prospect Capital Securities Limited and Prospect Finance Limited cashlessly exercised all of their remaining Pre-Funded Warrants and received 36,544,028 and 14,876,330 CDT Equity Common shares, respectively. Mark Taylor is the sole director and shareholder of both entities and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
CDT Equity Inc. filed an initial ownership report showing that Prospect Capital Securities Limited and Prospect Finance Limited hold Common Stock and Pre-Funded Warrants received as consideration in a Securities Purchase Agreement dated February 19, 2026, related to Sarborg Limited.
Prospect Capital received 198,749 shares of Common Stock and Pre-Funded Warrants to purchase up to 36,551,817 shares of Common Stock in exchange for 339 Sarborg shares. Prospect Finance received 127,209 shares of Common Stock and Pre-Funded Warrants to purchase up to 24,578,432 shares in exchange for 218 Sarborg shares.
The Pre-Funded Warrants have an exercise price of $0.0001 per share, are subject to shareholder approval and a 49.99% beneficial ownership limitation, have no expiration date, and will be exercisable once approved until exercised in full. Mark Taylor, as sole director and shareholder of both entities, may be deemed to beneficially own these securities, but disclaims beneficial ownership except to the extent of his pecuniary interest.